Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Wednesday. The stock had previously closed at $40.00, but opened at $37.70. Zealand Pharma A/S shares last traded at $37.70, with a volume of 334 shares.

Analysts Set New Price Targets

Several research firms have recently commented on ZLDPF. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Zealand Pharma A/S Stock Down 1.1%

The firm’s 50 day moving average is $46.41 and its 200-day moving average is $46.33. The firm has a market cap of $2.70 billion, a PE ratio of 6.25 and a beta of 0.95. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.